BsAbs are a promising treatment option for patients with relapsed DLBCL after the failure of second- or later-line therapies and have demonstrated that they are effective even in a subset of patients who relapsed after treatment with CD19 CAR T-cells [10]. Here, CD19 is linked to diffuse large B-cell lymphoma.